GenVec (GNVC) Stock Price, News & Analysis

Company Overview

GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

Key Stats

• Today's Range: $7.19 to $7.19
• 50-Day Range: N/A
• 52-Week Range: $2.70 to $10.44
• Volume: N/A
• Average Volume: 259,136 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNVC Stock Analysis - Frequently Asked Questions

How were GenVec's earnings last quarter?

GenVec Inc (NASDAQ:GNVC) announced its earnings results on Friday, November, 4th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.03. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.07 million.

When did GenVec's stock split?

GenVec shares reverse split on the morning of Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of GenVec own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GenVec investors own include Meta Platforms (META), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), NVE (NVEC), Microbot Medical (MBOT) and Pluristem Therapeutics (PSTI).

Company Calendar

• Last Earnings: 11/04/2016
• Today: 6/21/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:GNVC
• CIK: 934473
• Web: www.genvec.com
• Phone: +1-240-6320740
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A